Alpha 2.0
Login Register
» Authors » Borje Andersson

Borje Andersson

Explore the profile of Borje Andersson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 669
Followers 0
Related Specialties
Oncology
Hematology
Top 10 Co-Authors
Richard Champlin
Chitra Hosing
Marcos de Lima
Paolo Anderlini
Uday Popat
Partow Kebriaei
Sergio Giralt
Issa Khouri
Gabriela Rondon
Elizabeth J Shpall
Published In
Biol Blood Marrow Transplant
Blood
Oncotarget
Clin Lymphoma Myeloma Leuk
Anticancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens
Maymani H, Lin P, Saliba R, Popat U, Bashir Q, Shah N, et al.
Biol Blood Marrow Transplant . 2019 Jan; 25(5):1039-1044. PMID: 30639822
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for patients with multiple myeloma, as it provides a graft-versus-myeloma effect alongside a myeloma-free graft. Although reduced-intensity conditioning regimens decrease...
2.
Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution
Kellner J, Delemarre E, Yvon E, Nierkens S, Boelens J, McNiece I, et al.
Oncotarget . 2018 Nov; 9(86):35611-35622. PMID: 30479692
Incubation of umbilical cord blood (UCB) derived regulatory T-cells (Tregs) with fucosyltransferase enzyme improves their ability to home to the target tissue to prevent graft vs. host disease (GVHD). We...
3.
Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China
Huang X, Liu K, Ritchie D, Andersson B, Lu J, Hou J, et al.
Oncotarget . 2017 Apr; 8(25):41620-41630. PMID: 28404929
This report serves as a snapshot of the state-of-knowledge in the Asia Pacific (APAC) Hematology Oncology community, and establishes a baseline for longitudinal investigations to follow changes in best practices...
4.
A subset of virus-specific CD161 T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML
Alsuliman A, Muftuoglu M, Khoder A, Ahn Y, Basar R, Verneris M, et al.
Blood . 2016 Nov; 129(6):740-758. PMID: 27821506
The establishment of long-lived pathogen-specific T cells is a fundamental property of the adaptive immune response. However, the mechanisms underlying long-term persistence of antigen-specific CD4 T cells are not well-defined....
5.
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation
Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, et al.
Blood . 2016 Jun; 128(2):297-312. PMID: 27247137
The ability of cord blood transplantation (CBT) to prevent relapse depends partly on donor natural killer (NK) cell alloreactivity. NK effector function depends on specific killer-cell immunoglobulin-like receptors (KIR) and...
6.
Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China
Lu J, Hou J, Liu K, Parmar S, De La Fuente A, Andersson B, et al.
Leuk Lymphoma . 2016 Feb; 57(7):1534-8. PMID: 26887657
The Asia-Pacific Hematology Consortium (APHCON), in partnership with MDRingTM, a mobile global physician education network, has initiated a detailed longitudinal study of physician knowledge and practice preferences in the Asia-Pacific...
7.
Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation
Oran B, Jimenez A, de Lima M, Popat U, Bassett R, Andersson B, et al.
Biol Blood Marrow Transplant . 2015 Apr; 21(8):1405-1412. PMID: 25840338
We evaluated the prognostic significance of a modified European LeukemiaNet (ELN) classification for patients with acute myelogenous leukemia (AML) undergoing hematopoietic stem cell transplantation (HSCT) while in first complete remission...
8.
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies
Alousi A, Brammer J, Saliba R, Andersson B, Popat U, Hosing C, et al.
Biol Blood Marrow Transplant . 2015 Feb; 21(5):906-12. PMID: 25667989
Graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (CY) after ablative HLA-matched bone marrow (BM) transplantation has been reported to have comparable rates of acute GVHD with an apparent reduction in...
9.
Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation
Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, et al.
Biol Blood Marrow Transplant . 2014 Jun; 20(10):1618-25. PMID: 24953017
We investigated the impact of patient and disease characteristics, including cytogenetics, previous therapy, and depth of response, on the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with...
10.
Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes
Oran B, Popat U, Andersson B, Champlin R
Clin Lymphoma Myeloma Leuk . 2013 Dec; 13 Suppl 2:S282-8. PMID: 24290213
Allogeneic stem cell transplantation (SCT) is the only treatment with curative potential for myelodysplastic syndrome (MDS). The availability of SCT has been expanded with the introduction of reduced intensity conditioning...